COMPOSITION CONTAINING PEPTIDE OR PEPTIDE COMPOUND AS ACTIVE INGREDIENT, AND MEDICAL USE THEREFOR

Abstract

The present invention relates to a composition for preventing or treating an inflammatory disease induced by an autoimmune response, the composition comprising a peptide or a peptide mixture as an active ingredient. More specifically, the composition containing, as an active ingredient, peptide P1 to P5 or a mixture thereof may be provided as a treatment agent for an inflammatory disease induced by an autoimmune response, as alleviation of a skin ulcer and skin inflammation in a mouse model with psoriasis was confirmed and an inflammatory symptom in a model with enteritis was alleviated as results of intraperitoneally injecting or applying, as an externally administered agent on the skin, peptide P1 to P5 or the mixture thereof to the mouse animal models with psoriasis and the inflammatory bowel disease, which are inflammatory diseases induced by an autoimmune response.

Claims

1. A pharmaceutical composition for preventing or treating a disease selected from the group consisting of psoriasis, inflammatory bowel disease, Crohn's disease, allergic asthma, atopic dermatitis, and systemic inflammatory response syndrome, comprising a peptide comprising an amino acid sequence represented by SEQ ID NO: 1, a peptide comprising an amino acid sequence represented by SEQ ID NO: 2, a peptide comprising an amino acid represented by SEQ ID NO: 3, a peptide comprising an amino acid represented by SEQ ID NO: 4, a peptide comprising an amino acid represented by SEQ ID NO: 5, or a mixture thereof as an active ingredient.

2. The pharmaceutical composition of claim 1, wherein the peptide prevents or alleviates inflammation induced by an autoimmune response.

3. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is a formulation selected from the group consisting of oral preparations, external preparations, suppositories, and injections.

4. A health food for preventing or alleviating a disease selected from the group consisting of psoriasis, inflammatory bowel disease, Crohn's disease, allergic asthma, atopic dermatitis, and systemic inflammatory response syndrome, comprising a peptide comprising an amino acid sequence represented by SEQ ID NO: 1, a peptide comprising an amino acid sequence represented by SEQ ID NO: 2, a peptide comprising an amino acid represented by SEQ ID NO: 3, a peptide comprising an amino acid represented by SEQ ID NO: 4, a peptide comprising an amino acid represented by SEQ ID NO: 5, or a mixture thereof as an active ingredient.

Description

BRIEF DESCRIPTIONS OF THE DRAWINGS

[0011] FIG. 1 shows a result of FACS analysis identifying the frequency of CD40+ cells and CD83+ cells which are markers for dendritic cell activation among peripheral blood cells after administration of a peptide mixture to a mouse animal model with psoriasis.

[0012] FIG. 2 shows a result of FACS analysis identifying the frequency of RORγt-expressing cells among peripheral blood cells after administration of a peptide mixture to a mouse animal model with psoriasis.

[0013] FIG. 3 shows a result of FACS analysis identifying the frequency of regulatory T cells among peripheral blood cells after administration of a peptide mixture to a mouse animal model with psoriasis.

[0014] FIG. 4 shows a result of FACS analysis identifying the frequency of Ly6G-expressing neutrophils among abdominal macrophages after administration of a peptide mixture to a mouse animal model with psoriasis.

[0015] FIG. 5 shows a result of FACS analysis identifying the frequency of CD8+NK1.1+ cells among lymphocytes isolated from lymph nodes after administration of a peptide mixture to a mouse animal model with psoriasis.

[0016] FIG. 6 shows results of checking symptoms of inflammation after administration of a control, a control cream, and a peptide P124 in the form of external skin preparations for 5 days to the skin of a mouse animal model with psoriasis.

[0017] FIG. 7 shows results of observing the change in the size of spleen after oral administration of a peptide mixture to a mouse animal model with enteritis induced with dextran sulfate sodium (DSS).

[0018] FIG. 8 shows results of FACS analysis identifying the frequency of CD40+ cells and CD83+ cells which are markers for dendritic cell activation among peripheral blood cells and the frequency of CD83+ cells and CD86+ cells among intraperitoneal macrophages, after oral administration of a peptide mixture to a mouse animal model with enteritis.

[0019] FIG. 9 shows results of FACS analysis identifying the frequency of CD11b+ cells as a marker for macrophages among intraperitoneal macrophages, the frequency of NK1.1+ cells as a marker for natural killer cells among splenocytes, the frequency of cells expressing Ly6G+ as a marker for neutrophils, and the frequency of cells expressing ROR gammaT as a gene involved in Th17+ cell differentiation, after oral administration of a peptide mixture to a mouse animal model with enteritis.

[0020] FIG. 10 shows a result of identifying the frequency of fluorescence-labeled cells among intraperitoneal macrophages 48 and 72 hours after oral administration of peptides 1, 2, and 4 each conjugated with different fluorescence to normal mice.

BEST MODE

[0021] Hereinafter, an example embodiment of the present disclosure will be described in more detail.

[0022] An example embodiment of the present disclosure may provide a pharmaceutical composition for preventing or treating a disease selected from the group consisting of psoriasis, inflammatory bowel disease, Crohn's disease, allergic asthma, atopic dermatitis, and systemic inflammatory response syndrome, comprising a peptide having an amino acid sequence represented by SEQ ID NO: 1, a peptide having an amino acid sequence represented by SEQ ID NO: 2, a peptide having an amino acid represented by SEQ ID NO: 3, a peptide having an amino acid represented by SEQ ID NO: 4, a peptide having an amino acid represented by SEQ ID NO: 5, or a mixture thereof as an active ingredient.

[0023] The peptide may prevent or alleviate inflammation induced by an autoimmune response.

[0024] The pharmaceutical composition may be a formulation selected from the group consisting of oral preparations, external preparations, suppositories, and injections, but is not limited thereto.

[0025] In an example embodiment of the present disclosure, the pharmaceutical composition may further include one or more additives selected from the group consisting of carriers, excipients, disintegrants, sweeteners, coating agents, swelling agents, glydents, flavoring agents, antioxidants, buffers, bacteriostatic agents, diluents, dispersants, surfactants, binders, and lubricants appropriate to be commonly used in the preparation for pharmaceutical compositions.

[0026] Specifically, lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil may be used as the carriers, excipients and diluents. Solid preparations for oral administration may include tablets, pills, powder, granules and capsules, wherein such solid preparation may be prepared by mixing at least one excipient in the composition, for example, starch, calcium carbonate, sucrose or lactose, and gelatin. In addition, lubricants such as magnesium stearate and talc may be used in addition to simple excipients. A liquid formulation for oral dosage may include suspensions, solutions, emulsions, and syrups, and various excipients such as wetting agents, sweeteners, fragrances, and preservatives may be included in addition to water and liquid paraffin, which are commonly used simple diluents. The formulation for parenteral administration may include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried formulations, and suppositories. Propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used as the non-aqueous solvents and suspensions. Witepsol, macrogol, Tween 61, cacao butter, laurin fat, and glycerogelatin may be used as a base of the suppositories.

[0027] According to an example embodiment of the present disclosure, the pharmaceutical composition may be administered to a subject in a conventional manner via intravenous, intraarterial, intraperitoneal, intramuscular, intrasternal, transdermal, intranasal, inhalational, topical, rectal, oral, intraocular or intradermal routes.

[0028] The preferred dosage of the peptide may vary depending on condition and weight of the subject, the type and severity of the disease, the drug form, and the route and duration of administration, and may be appropriately selected by those skilled in the art. According to an example embodiment of the present disclosure, although not limited thereto, the daily dose may be 0.01 μg/kg to 200 mg/kg, specifically 0.1 to 200 mg/kg, more specifically 0.1 to 100 mg/kg. Administration may be performed once a day or several times in divided doses, but not limiting the scope of the present disclosure thereby.

[0029] In an example embodiment of the present disclosure, the ‘subject’ may be a mammal including a human, but is not limited to the examples.

[0030] An example embodiment of the present disclosure provides a health food for preventing or alleviating a disease selected from the group consisting of psoriasis, inflammatory bowel disease, Crohn's disease, allergic asthma, atopic dermatitis, and systemic inflammatory response syndrome, comprising a peptide having the amino acid sequence represented by SEQ ID NO: 1, a peptide having the amino acid sequence represented by SEQ ID NO: 2, a peptide having the amino acid represented by SEQ ID NO: 3, a peptide having the amino acid represented by SEQ ID NO: 4, a peptide having the amino acid represented by SEQ ID NO: 5, or a mixture thereof as an active ingredient.

[0031] The health food may be used together with other food or food additives in addition to the peptide or a mixture thereof, and may be appropriately used according to a conventional method. The compound amount of the active ingredient may be appropriately determined depending on the intended use thereof, for example, prevention, health or therapeutic treatment.

[0032] The effective dose of the compound contained in the health food may be applied according to the effective dose of the therapeutic agent, but in the case of long-term intake for health and hygiene or health control, it may be less than or equal to the above range. However, it is clear that the active ingredient may be used in an amount beyond the above range since there is no problem in terms of safety.

[0033] The type of health food is not particularly limited, and examples include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, various soups, beverages, tea, drinks, alcoholic beverages, and vitamin complexes.

Modes for Carrying Out Invention

[0034] Hereinafter, examples will be described in detail to help the understanding of the present disclosure. However, the following examples are merely illustrative of the content of the present disclosure, and the scope of the present disclosure is not limited to the following examples. The examples of the present disclosure are provided to more completely explain the present disclosure to those skilled in the art.

<Example 1> Preparation of Peptides

[0035] With efforts to develop a low-molecular substance for the treatment of inflammation from snake venom, particularly a substance known as a protein, peptides with medicinal effects have been discovered. Peptides having the following 11 to 23 amino acid sequences were prepared.

TABLE-US-00001 P1: (SEQ ID NO: 1) LICPEKYCNKVHT P2: (SEQ ID NO: 2) YCNKVHTCRNG P3: (SEQ ID NO: 3) PREIVECCSTDKCNH P4: (SEQ ID NO: 4) HTCRNGENICF P5: (SEQ ID NO: 5) ENICFKRFYEGNLLGKRYPRGCA

<Example 2> Identification of Effect of Peptides in Mouse Model with Psoriasis

[0036] 20 μg/day/mouse of imiquimod (IMQ) was administrated to C56BL/6J mice as an external skin preparation once a day for 6 days to induce symptoms of psoriasis.

[0037] A peptide mixture (P124) and the control cream were administrated daily for 5 days as an external skin preparation to check characteristics of immune cells, wherein the peptide mixture was obtained by mixing peptides P1, P2, and P4 isolated in Example 1 with physiological saline for injection so as to be 1 μg respectively.

[0038] As a result of analyzing peripheral blood cells by flow cytometry (FACS) after administration of the peptide, it was found that the frequency of CD40 positive (+) cells and CD83+ cells which are markers for dendritic cell activation decreased as shown in FIG. 1. In addition, a decrease in the frequency of cells expressing RORγt was detected as shown in FIG. 2. RORγt is a marker for Th17 cells, and an increase in Th17 cells is associated with aggravation of psoriasis.

[0039] In addition, as shown in FIG. 3, it was found that the frequency of regulatory T cells having a function of suppressing the inflammatory response increased in the peptide-administered group.

[0040] As a result of analyzing the intraperitoneal macrophages by flow cytometry (FACS) after administration of the peptides, it was found that the frequency of neutrophils expressing Ly6G decreased as shown in FIG. 4. Excessive expression of neutrophils is known to cause excessive inflammatory response due to excessive secretion of cytokines.

[0041] As a result of analyzing lymphocytes isolated from lymph nodes by flow cytometry (FACS) after administration of peptides, it was found that the frequency of CD8+NK1.1+ cells decreased as shown in FIG. 5. CD8+NK1.1+ cells secrete IFNγ and are involved in innate immune response to control microbial pathogens. However, excessive expression thereof is known to be associated with induction of inflammation.

[0042] However, as a result of comparing symptomatic changes after daily administration of the control, the control cream, and the peptide mixture (P124) as external skin preparations for 5 days to a mouse animal model induced with psoriasis symptoms, inflammatory symptoms appeared on the skin after 6 days in the control and control cream group as shown in FIG. 6, but it was found that psoriasis symptoms barely remained in the peptide-treated group.

<Example 3> Identification of Effect of Peptides in Animal Model with Inflammatory Bowel Disease

[0043] The peptide mixture (P124) obtained by mixing the peptides P1, P2 and P4 isolated in Example 1 with physiological saline for injection to be 1 μg respectively was orally administered to a mouse animal model with enteritis induced by dextran sulfate sodium (DSS) once a day for 4 consecutive days.

[0044] As a result of spleen extraction in mice orally administered with the peptide mixture (P124), it was found that the size of spleen was reduced as shown in FIG. 7.

[0045] In addition, as a result of observing the immune cells in the mouse model with enteritis with the peptide mixture administered, the frequency of CD40+ dendritic cells and CD86+ dendritic cells decreased among peripheral blood cells as shown in FIG. 8, and the frequency of CD83+ cells and CD86+ cells also decreased among intraperitoneal macrophages due to administration of the peptides.

[0046] It is known that overexpression of dendritic cell activation markers is associated with prolonged chronic inflammation, and it was found that peptide administration decreased the dendritic cell activation markers from above results, thereby alleviating symptoms of inflammatory bowel diseases through administration of the peptide.

[0047] In addition, as shown in FIG. 9, it was found that the frequency of CD11b+ cells as a macrophage marker decreased among intraperitoneal macrophages after administration of the peptide to the mouse model with enteritis, and a decrease in the frequency of CD11b+ cells was observed in splenocytes as well. In splenocytes, the frequency of NK1.1+ cells as a marker for natural killer cells increased, and the frequency of cells expressing Ly6G+ cells as a marker for neutrophils decreased. The frequency of cells expressing ROR gammaT, a gene involved in Th17+ cell differentiation, decreased.

[0048] From the results above, it was found that the peptide of the present disclosure may alleviate symptoms of colitis by decreasing the frequency of inflammation inducing cells.

[0049] Furthermore, peptides 1, 2, and 4 were orally administered to normal mice after conjugation with each different fluorescence, and the frequency of fluorescence-labeled cells was measured among intraperitoneal macrophages after 48 and 72 hours.

[0050] As a result, as shown in FIG. 10, P2 and P4 peptides were maintained up to 48 hours, and P1 was maintained up to 72 hours.

[0051] From the above results, it was found that the orally administered peptide reached the intraperitoneal cavity to be involved in the immune response, thereby inducing the alleviation of symptoms of colitis.

[0052] Although specific parts of the present disclosure have been described in detail above, it is clear for those skilled in the art that these specific descriptions are merely preferred example embodiments and the scope of the present disclosure is not limited thereto. Accordingly, the substantial scope of the present disclosure may be defined by the appended claims and equivalents thereof.